China National Pharmaceutical Group


China National Pharmaceutical Group Corp. known as Sinopharm is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group, . Shanghai Shyndec Pharmaceutical and Beijing Tiantan Biological Products.
China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.
Several Sinopharm's subsidiary, such as China Sinopharm International Corp. and China National Pharmaceutical Foreign Trade Corp. were remained unlisted, which was not injected to Sinopharm Group.
Sinopharm was ranked 205th in 2016 Fortune Global 500 list.

History

China National Pharmaceutical Corporation
One of its subsidiaries is the Wuhan Institute of Biological Products Co Ltd. a biotechnology company based in Wuhan, specializing in vaccines. It was fined for selling 400,520 ineffective DPT vaccines in November 2017.

China National Pharmaceutical Group Corporation

China National Pharmaceutical Group Corporation was founded in 1998 as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation, China National Pharmaceutical Foreign Trade Corp. and China National Medical Device. In 2009 it was merged with China National Biotec Group.